Login
← Go Back
Marksans Pharma
MARKSANS · Pharma > Pharmaceuticals & Drugs · Chairman: Mark Saldanha · MD: Mark Saldanha · Listing date: Jan. 22, 2002 · Employees: 1138 · Mumbai · http://www.marksanspharma.com
Stock Price vs Company Growth
1d
0.5%
1w
5.8%
1m
13.4%
3m
3.8%
6m
22.1%
1y
45.8%
5y
64.1%
10y
15.4%
all
18.6%
Created with Highcharts 8.2.2SalesProfitPriceDividendQtr SalesOperating CashflowDec10Jun14Dec17Jun21Latest
🤔 How to analyze this graph?
Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price
₹ 239 0.5%
168
246
Company Overview
Sales
2,474 Cr
Growth: 17.4%
Profit after Tax
368 Cr
Growth: 6.1%
Mid Cap
10,846 Cr
P/E: 29.4x
Industry P/E: 33.0x
Created with Highcharts 8.2.2HistoricalGrowthValuationAttractivenessProfitabilityIndustryOutlookPriceStability10
Fundamentals
Sales (Cr) ₹ 2,474
Growth 17.4%
EBITDA 20.7%
P/S 4.4x
Dividend 0.2%
P/E 29.4x
Book Value ₹ 52
PEG Ratio 1.7x
ROE 16.7%
P/B 4.6x
Shareholding Pattern
Institutions
Created with Highcharts 8.2.2Dec19Mar20Jun20Sep20Dec20Mar21Mar22Dec22
Promoters
Mark Saldanha
48.25 %
Created with Highcharts 8.2.2Dec19Mar20Jun20Sep20Dec20Mar21Mar22Dec22
Others
Mukul Mahavir Prasad Agrawal
1.47 %
Created with Highcharts 8.2.2Dec19Mar20Jun20Sep20Dec20Mar21Mar22Dec22
Increase    Decrease    No change
Company Profile Detailed
Marksans Pharma, incorporated in 1992, was a wholly-owned subsidiary of Glenmark Pharmaceuticals. It became a separate entity in March 2003 and the name was changed to Marksans Pharma in 2005.Currently the company has presence in Active Pharmaceuticals Ingredients (APIs), formulations and biopharmaceuticals. It is also actively engaged in research and development and offers contract research and manufacturing services (CRAMS) to global pharmaceutical companies.
Belongs to (10 Indices) view more
Investors (39)
kaushik5
ashish.k...
fii.s1
Followers (7)
akash2
karan3
sachin3